SGLT2 Inhibitors May Lead to Better Kidney Outcomes Than GLP-1 DrugsSGLT2 Inhibitors May Lead to Better Kidney Outcomes Than GLP-1 Drugs
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with a lower risk of adverse kidney outcomes than glucagon-like peptide-1 (GLP-1) receptor agonists in people with type 2 diabetes in a recent study that emulated a clinical trial. Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with a lower risk of adverse kidney outcomes than glucagon-like peptide-1 (GLP-1) receptor agonists Read More
Risk-Based vs Annual Breast Cancer ScreeningRisk-Based vs Annual Breast Cancer Screening
This randomized clinical trial examines whether risk-based screening is a safe and effective alternative to annual mammography for detecting breast cancer in women 40 years and older.
Unlocking the Potential of Risk-Based Screening for Breast CancerUnlocking the Potential of Risk-Based Screening for Breast Cancer
Breast cancer is the most frequently diagnosed malignant neoplasm among women in the US and remains a leading cause of cancer mortality. In 2025, an estimated 316 950 women were diagnosed with invasive disease and 42 170 died, reflecting a lifetime risk of approximately 1 in 8. These patterns in breast cancer morbidity and mortality underscore the continued need for advances in prevention, screening, and treatment.
Risk-Based vs Annual Breast Cancer Screening Research SummaryRisk-Based vs Annual Breast Cancer Screening Research Summary
This trial aimed to assess whether risk-based screening is as safe, less morbid, and as acceptable to women as annual screening for breast cancer detection.
What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer SurvivorsWhat Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors
This Viewpoint discusses the benefits and risks of systemic hormone therapy in breast cancer survivors following the US Food and Drug Administration’s removal of black box warnings from menopausal hormone therapy.
Quarter of healthy years lost to breast cancer are due to lifestyle factors, research findsQuarter of healthy years lost to breast cancer are due to lifestyle factors, research finds
Largest study of its kind suggests high red meat consumption has biggest impact, followed by smokingMore than a quarter of healthy years lost to breast cancer are due to lifestyle factors such as red meat intake and smoking, according to the largest study of its kind.The study, published in the Lancet Oncology, used data from population-based cancer registries to produce a comprehensive analysis of breast cancer and its risk factors. Continue reading…
Breast cancer still most common cancer among women worldwide, with annual cases expected to exceed 3.5 million by 2050Breast cancer still most common cancer among women worldwide, with annual cases expected to exceed 3.5 million by 2050
Despite recent advancements in breast cancer treatments, new breast cancer cases in women are predicted to rise by a third globally from 2.3 million in 2023 to more than 3.5 million in 2050. Similarly, yearly deaths from the disease are projected to surge 44%, from around 764,000 to 1.4 million, with disproportionate impact in countries with limited resources, according to a major new analysis from the Global Burden of Disease Study Breast Cancer Collaborators, published in The Lancet Oncology.
Breast cancer screening with MRI provides modest benefit for high-risk womenBreast cancer screening with MRI provides modest benefit for high-risk women
1. For women at higher-than-average risk, adding supplemental MRI to DBT provided only modest additional benefit, resulting in a similar harm-benefit balance compared with DBT alone. 2. Across all risk levels, biennial DBT starting at age 50 was the most cost-effective strategy. Evidence Rating Level: 2 (Good) Study Rundown: A substantial proportion of women undergoing
The post Breast cancer screening with MRI provides modest benefit for high-risk women first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
GLP-1 Drugs May Work Differently in WomenGLP-1 Drugs May Work Differently in Women
(MedPage Today) — Women lost more weight than men while using GLP-1 receptor agonists, a systematic review and meta-analysis of randomized clinical trials showed. Among six trials that analyzed outcomes for nearly 20,000 participants by sex… (MedPage Today) — Women lost more weight than men while using GLP-1 receptor agonists, a systematic review and Read More
GLP-1 drugs associated with reduced need for emergency care for migraineGLP-1 drugs associated with reduced need for emergency care for migraine
For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study being presented at the American Read More